[go: up one dir, main page]

WO1997016426A1 - Arylpyrroles substitues, compositions contenant ces composes et procedes d'utilisation desdits composes - Google Patents

Arylpyrroles substitues, compositions contenant ces composes et procedes d'utilisation desdits composes Download PDF

Info

Publication number
WO1997016426A1
WO1997016426A1 PCT/US1996/017477 US9617477W WO9716426A1 WO 1997016426 A1 WO1997016426 A1 WO 1997016426A1 US 9617477 W US9617477 W US 9617477W WO 9716426 A1 WO9716426 A1 WO 9716426A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
aryl
conr
compound
Prior art date
Application number
PCT/US1996/017477
Other languages
English (en)
Inventor
Stephen E. De Laszlo
Nathan B. Mantlo
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602835.2A external-priority patent/GB9602835D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU75290/96A priority Critical patent/AU7529096A/en
Publication of WO1997016426A1 publication Critical patent/WO1997016426A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • Cytokine mediated diseases refers to diseases or conditions in which excessive or unregulated production of one or more cytokines occurs.
  • Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Tumor Necrosis Factor (TNF) are cytokines which are involved in immunoregulation and other physiological conditions, such as inflammation.
  • IL-1 , IL-8, IL-6 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions.
  • IL-1 is implicated. Included among these diseases are rheumatoid arthritis, osteoarthritis, endotoxemia, toxic shock syndrome, other acute or chronic inflammatory diseases, such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes and pancreatic ⁇ cells.
  • TNF production has been implicated in mediating or exacerbating rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases, reperfusion injury, graft v.
  • host rejection such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS related complex (ARC), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • AIDS related complex ARC
  • keloid formation scar tissue formation, Crohn's disease, ulcerative colitis and pyresis.
  • Monokines such as TNF
  • TNF have been shown to activate HIV replication in monocytes and/or macrophages [See Poli, et al., Proc. Natl. Acad. Sci., 87:782-784 (1990)]
  • inhibition of monokine production or activity aids in limiting HIV progression as stated above for T-cells.
  • TNF has also been implicated in various roles with other viral infections, such as the cytomegalia virus (CMV), influenza virus, and the herpes virus for similar reasons as those noted.
  • CMV cytomegalia virus
  • IL-6 is a cytokine effecting the immune system and hematopoiesis. It is produced by several mammalian cell types in response to agents such as IL-1 and is correlated with disease states such as angiofollicular lymphoid hyperplasia.
  • Interleukin-8 is a chemotactic factor first identified and characterized in 1987. Many different names have been applied to IL-8, such as neutrophil attractant/activation protein-1 (NAP-1 ), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor. Like IL-1 , IL-8 is produced by several cell types, including mononuclear cells, fibroblasts, endothelial cells and keratinocytes. Its production is induced by IL-1 , TNF and by lipopolysaccharide (LPS). IL-8 stimulates a number of cellular functions in vitro.
  • NAP-1 neutrophil attractant/activation protein-1
  • MDNCF monocyte derived neutrophil chemotactic factor
  • NAF neutrophil activating factor
  • T-cell lymphocyte chemotactic factor T-cell lymphocyte chemotactic factor.
  • IL-8 is produced by several cell types, including
  • the present invention is directed to a compound represented by formula I:
  • each R a independently represents a member selected from the group consisting of: halo; CN, NO2, R 21 ; OR 23 ; SR 2 3; S(O)R 21 ; SO 2 R 21 ; NR 20 R 23 ; NR 20 COR 21 ; NR 20 CO 2 R 21 ; NR 20 CONR 20 R 23 ;
  • R 1 is selected from the group consisting of: H; C 1 -15 alkyl, C 3- 15 alkenyl, C 3-15 alkynyl, aryl and heterocyclyl, said alkyl, alkenyl, aryl, alkynyl and heterocyclyl being optionally substituted with from one to three members selected from the group consisting of: aryl, heteroaryl, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 2 -, SO 2 R 21 , SO 2 NR 20 R 2 3.
  • R 2 is selected from the group consisting of: heterocyclyl; C 1 - 15 alkyl, C 2- 15 alkenyl, and C 2- 15 alkynyl, said alkyl, alkenyl and alkynyl groups being optionally interrupted by 1 -2 oxo groups or heteroatoms selected from O, S, S(O), SO 2 or NR 24 ; said alkyl, alkenyl, alkynyl and heterocyclyl being optionally substituted with from 1 -3 of halo, aryl, aryl(R a )3, heteroaryl, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 ,
  • R 3 is selected from the group consisting of: CN, S(O)R 21 , SO 2 R 21 , COR 20 , SO 2 N(R 20 ) 2 , SO 2 NR 20 COR 21 , SO 2 NR 20 CON(R 20 ) 2 , CO 2 R 20 , CONR 20 R 23 , CONR 20 SO 2 R 21 and SO 2 NR 20 CO 2 R 21 ;
  • R 20 represents a member selected from the group consisting of: H, C 1 - 15 alkyl, C 3- 15 alkenyl, C 3- 15 alkynyl, heterocyclyl, aryl and heteroaryl, said alkyl, alkenyl and alkynyl being optionally substituted with 1-3 groups selected from halo, aryl and heteroaryl;
  • R 21 represents a member selected from the group consisting of: C 1 - 15 alkyl, C 3- 15 alkenyl, C 3- 15 alkynyl, optionally interrupted by 1-2 heteroatoms selected from O, S, S(O), SO 2 or NR 24 ; heterocyclyl, aryl and heteroaryl;
  • alkyl, alkenyl, alkynyl, heterocyclyl, aryl and heteroaryl being optionally substituted with from 1-3 of halo, heterocyclyl, aryl, heteroaryl, CN, OR 20 , O((CH 2 ) n O) m R 20 , NR 20 ((CH 2)n O) m R 20 wherein n represents an integer of from 2 to 4, and m represents an integer of from 1 to 3; SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 ,
  • R 22 is selected from the group consisting of: C 1 - 15 alkyl, C 2- 15 alkenyl, C 2- 15 alkynyl, heterocyclyl, aryl and heteroaryl, said alkyl, alkenyl, and alkynyl being optionally substituted with 1 -3 halo, aryl or heteroaryl groups;
  • R 23 is R 21 or H;
  • R 24 is selected from aryl, COR 22 , CO 2 R 22 , CON(R 20 ) 2, R 23 and SO 2 R 22 ; and in a functional group substituent, when two R 20 groups are present, when R 20 a n d R 21 are present, or when R 20 and R 23 are present, said two R 20 groups, R 20 and R 21 or said R 20 and R 23 may be taken in combination with the atoms to which they are attached and any intervening atoms and represent heterocyclyl containing from 5-10 atoms, at least one atom of which is a heteroatom selected from O, S or N, said hetercyclyl optionally containing 1-3 additional N atoms and 0-1 additional O or S atom.
  • composition which is comprised of a compound of formula I in
  • cytokine mediated disease in a mammal, comprising administering to a mammalian patient in need of such treatment an amount of a compound of formula I which is effective to treat said cytokine mediated disease.
  • alkyl refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 15 carbon atoms unless otherwise defined. It may be straight, branched or cyclic.
  • Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl.
  • Preferred cycloalkyi groups include cyclopentyl and cyclohexyl.
  • Alkyl also includes a straight or branched alkyl group which contains or is interrupted by a cycloalkylene portion or a carbonyl group.
  • cycloalkylene interruption include the following: —
  • Examples of carbonyl interruption include - (CH 2 ) x -C(O)-(CH 2 ) y -.
  • the alkylene and monovalent alkyl portion(s) of the alkyl group can be attached at any available point of attachment to the cycloalkylene portion.
  • substituted alkyl when substituted alkyl is present, this refers to a straight, branched or cyclic alkyl group as defined above, substituted with 1 -3 groups as defined with respect to each variable.
  • alkenyl refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 15 carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic (non-resonating) carbon-carbon double bonds may be present.
  • Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted when a substituted alkenyl group is provided.
  • alkynyl refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 15 carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present.
  • Preferred alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted when a substituted alkynyl group is provided.
  • Aryl refers to aromatic rings e.g., phenyl, substituted phenyl and like groups as well as rings which are fused, e.g., naphthyl and the like.
  • Aryl thus contains at least one ring having at least 6 atoms, with up to two such rings being present, containing up to 10 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms.
  • the preferred aryl groups are phenyl and naphthyl.
  • Aryl groups may likewise be substituted as defined below.
  • Preferred substituted aryls include phenyl and naphthyl substituted with one or two groups.
  • the group represents a 5-10 membered aryl group substituted with 1 - 3 groups selected from R a .
  • Preferred Ar are phenyl and naphthyl.
  • heteroaryl refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S or N, in which a carbon or nitrogen atom is the point of attachment, and in which one additional carbon atom is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms.
  • the heteroaryl group is optionally substituted with up to three groups. Heteroaryl thus includes aromatic and partially aromatic groups which contain one or more heteroatoms.
  • the group represents a heteroaryl group which contains from 5 to 10 atoms.
  • One to three atoms are heteroatoms which are selected from O, S and N.
  • the heteroaryl group may be unsubstituted or substituted with 1 -3 R a groups.
  • HAr is carbon linked except where it is a purinyl, imidazolyl or imidazopyridine in which case it may be attached at the nitrogen or carbon atom.
  • Preferred heteroaryl groups represented by are as follows: pyridyl, quinolyl, purinyl, imidazolyl, imidazopyridyl and pyrimidinyl.
  • heterocycloalkyl and “heterocyclyl” refer to a cycloalkyi group (nonaromatic) in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N, and in which up to three additional carbon atoms may be replaced by said heteroatoms.
  • the heterocyclyl is carbon or nitrogen linked, if said heterocyclyl is carbon linked and contains a nitrogen, then nitrogen may be substituted with the variable group R24.
  • the group may be interrupted by or contain one or two carbonyls.
  • heterocyclyls are piperidinyl, morpholinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro- imidazo[4,5-c]pyridine, imidazolinyl, piperazinyl, pyrrolidine-2-one, piperidine-2-one and the like.
  • TNF mediated disease or disease state refer to any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1 or IL-6.
  • cytokine as used herein is meant any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response.
  • a cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF- ⁇ ) and Tumor Necrosis Factor-beta (TNF- ⁇ ).
  • IL-1 Interleukin-1
  • IL-6 Interleukin-6
  • TNF- ⁇ Tumor Necrosis Factor-alpha
  • TNF- ⁇ Tumor Necrosis Factor-beta
  • cytokine interfering and "cytokine suppresive amount” mean an effective amount of a compound of formula I which decreases in the in vivo levels or activity of the cytokine to normal or sub-normal levels, when given to the patient for the prophylaxis or therapeutic treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production or activity.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All such compounds are included in the present invention.
  • One subset of compounds of the invention relates to compounds of formula I wherein Ar represents a substituted phenyl group. Within this subset, all other variables are as originally defined.
  • R a is selected from the group consisting of: halo; CN, R 21 ; OR 23 ; CO 2 R 23 ; CONR 20 R 23 and tetrazol-5-yl.
  • Another subset of compounds of the invention relates to compounds of formula I wherein HAr represents a substituted or unsubstituted pyridyl, quinolyl, purinyl, imidazolyl or imidazopyridyl group. Within this subset, all other variables are as originally defined.
  • Another subset of compounds of the invention relates to compounds of formula I wherein R 1 is H, C 1 - 15 alkyl or C 1- 15 alkyl substituted as originally defined. Within this subset, all other variables are as originally defined.
  • R 2 represents one of the following groups:
  • Another subset of compounds of the invention relates to compounds of formula I wherein R 3 represents CO 2 R 20 , CONR 20 R 23 or CN. Within this subset, all other variables are as originally defined.
  • R a represents a member selected from the group consisting of: halo; CN, R 2 1 ; OR 23 ; CO 2 R 23 ; CONR 20 R 23 and tetrazol-5-yl; HAr is an optionally substituted:
  • R 1 is:
  • R 2 is:
  • R 3 is: a) CO 2 R 20 ; b) CONR 20 R 23 or
  • a subset of the most preferred compounds of formula I is realized when: represents a member selected from the group consisting of:
  • g) 3-hydroxyphenyl represents a member selected from the group consisting of:
  • R 3 is selected from the group consisting of:
  • R 1 is C 1 - 15 alkyl
  • R 2 is selected from the group consisting of:
  • R 3 is selected from the group consisting of:
  • the pharmaceutically acceptable salts of the compounds of formula I include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of formula I formed e.g. from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric, toluene-sulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic and the like.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
  • the compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
  • This invention also relates to a method of inhibiting the production or activity of cytokines in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula I to inhibit cytokine production or activity, such that it is regulated down to treat, ameliorate or prevent the disease state.
  • the compounds of formula 1 can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of disease states in mammals, which are exacerbated or caused by excessive or unregulated cytokine production, more specifically IL-1 , IL-8 or TNF production, by such mammal's cell, such as but not limited to monocytes and/or macrophages.
  • Compounds of formula I inhibit proinflammatory cytokines, such as IL-1 , IL-8 and TNF and are therefore useful for treating inflammation diseases such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.
  • cytokines such as IL-1 , IL-8 and TNF
  • inflammation diseases such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.
  • the compounds of formula I may be used to treat other disease states mediated by excessive or unregulated TNF production.
  • diseases include, but are not limited to sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis.
  • bone resorption diseases such as osteoporosis, reperfusion injury, graft vs.
  • AIDS cytomegalia virus
  • influenza virus a virus that has a high degree of vacuna virus
  • herpes family of viruses such as Herpes Zoster or Simplex I and II.
  • the compounds of formula I may also be used topically in the treatment of inflammations such as for the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other
  • Interleukin-1 has been demonstrated to mediate a variety of biological activities thought to be important in immuno-regulation and other physiological conditions. [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)].
  • the myriad of known biological activities of IL- 1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.
  • the compounds of formula I are also useful in treating diseases characterized by excessive IL-8 activity.
  • diseases characterized by excessive IL-8 activity There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. These diseases include psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis.
  • the invention includes a method of treating psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis, in a mammal in need of such treatment which comprises administering to said mammal a compound of formula I in an amount which is effective for treating said disease or condition.
  • the compounds of formula I are normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • This invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier or diluent.
  • the compounds of formula I are
  • a compound of formula I administered in conventional dosage forms prepared by combining a compound of formula I with standard pharmaceutical carriers according to conventional procedures.
  • the compounds of formula I may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known in the art, such as glyceryl mono-stearate or glyceryl distearate, alone or with a wax.
  • the preparation can be in the form of a tablet, hard gelatin capsule, a troche or lozenge.
  • the amount of solid carrier will vary widely but preferably will be from about 0.025 mg to about 1 g.
  • the preparation is in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • the compounds of formula I may be administered topically.
  • the compounds of formula I may be administered topically in the form of a liquid, solid or semi-solid.
  • Liquids include solutions, suspensions and emulsions.
  • Solids include powders, poultices and the like.
  • Semi-solids include creams, ointments, gels and the like.
  • a representative, topical, antiinflammatory dose of a compound of formula I is from about 0.01 mg to about 2.0 g,
  • the active ingredient may comprise, for topical administration, from about 0.001 % to about 90% w/w.
  • Drops according to the present invention may comprise sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.
  • a suitable aqueous solution optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by aseptic technique.
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01 %) and chlorhexidine acetate (0.01 %).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • an agent to hasten drying and to cool the skin such as an alcohol or acetone
  • a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous liquid, with the aid of suitable machinery, with a greasy or non-greasy base.
  • the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof.
  • suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicas, and other ingredients such as lanolin may also be included.
  • the methods of the instant invention may be carried out by administering the compound of formula I to a patient in need of such treatment.
  • parenteral' as used herein includes intravenous, intramuscular, or intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • the instant invention can also be carried out by delivering the monokine activity interfering agent subcutaneous intranasally, intrarectally, transdermally, or intravaginally
  • the compounds of formula I may also be administered by inhalation.
  • inhalation' is meant intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by convention techniques.
  • Compound 1 is prepared as described below. Hetero aromatic aldehydes 3 are converted to their trimethylsilyl cyanohydrins 4.
  • the alkylating agent 7a is prepared by various methods such as: free radical or acid catalyzed bromination of a ketone; halogenation of a ketone enolate; conversion of the hydroxyl group of an alpha-hydroxy ketone to a leaving group such as the bromide, triflate, tosylate or mesylate; reaction of an acid chloride with diazomethane followed by reaction with hydrogen chloride gives an alpha-chloro ketone.
  • Ethanones 7 are prepared by addition of heteroaryl methyl anions 8 to activated benzoic acids 9 (for example esters, acid chlorides, nitriles and N-methoxy-N-methyl amides) (see: Wolfe, J. F. et al J. Org. Chem. 39, 2006 (1974) and Kaiser, E. M. et al. Synthesis 705 (1975) and Ohsawa A. Chem. Pharm. Bull. 26, 3633, (1978)).
  • benzoic acids 9 for example esters, acid chlorides, nitriles and N-methoxy-N-methyl amides
  • An alternative approach to 7 is via alkylation of aryl trimethyl silyl protected cyanohydrins 10.
  • Treatment of 10 with lithium diisopropyl amide in THF and addition of a heteroaryl methyl group functionalized with a leaving group L (for example:Br, I, Cl , tosylate, mesylate) followed by acid catalyzed hydrolysis of the silyl cyanohydrin group provides ethanones such as 7 (Deuchert, K.; Hertenstein, U.;
  • Dimethylacetal 10a may be prepared from aldehydes by reaction with trimethylorthoformate and an acid catalyst. Addition of a base such as butyl lithium followed by an alkylating agent after hydrolysis of the acetal, also provides 7.
  • 1,3 diketones 11 is prepared by alkylation of 4 with bromoacetophenones (See Scheme III).
  • 1 ,4 diketones 13 are also prepared as described above in Scheme IV.
  • a heteroaryl aldehyde 14 is condensed with a methyl ketone 15 to provide a, ⁇ -unsaturated ketone 16.
  • a catalyst such as cyanide or a thiazolium salt
  • an aryl aldehyde 17 reacts with 16 to give 13 (Stetter, H. J. et al Heterocyclic Chem. 14, 573, 1977 and Stetter, H. et. al. Organic Reactions, Vol 40, 407-496). Condensation of 13 with an amine provides compounds of formula I.
  • Intermediate 16 may be prepared by a Horner-Emmons reaction of the anion of 18 with the heteroaryl aldehyde 14.
  • the reagent 18 is prepared by reaction of the bromoketone 19 and triethyl phosphite or by reaction of the lithium salt of diethyl methylpho.sphonate with an ester 21.
  • ester and nitrile of formula I may be prepared as shown in Scheme VI by treatment of 1 ,2 disubstituted-2 halo ketones 23 with 24 with ammonia or an amine producing ester I (Hantzsch. Ber. Dtsch. Chem. Ges. 23, 1474, 1890). Alternatively a 2-amino ketone 25 reacts with 24 to produce I.
  • a further method of synthesis of Compounds of formula I is by oxidation and esterification of aldehyde 26.
  • the aldehyde is prepared by treatment of the R 3 -unsubstituted pyrrole 22 with the Villsmeyer reagent (POCl 3 /DMF).
  • the pyrrole 22 may be silylated on nitrogen to give 27 by treatment with a silyl chloride and base in a solvent such as methylene chloride.
  • the pyrrole 27 may then be sulphinylated with a sulphinyl-chloride under basic conditions to provide 28 (J. Org Chem 6317, 1990).
  • Oxidation of 28 with a reagent such as m-chloroperoxybenzoic acid or potassium persulfate will give the sulphone 29. Removal of the silyl group and derivatization of the pyrrole will give compounds of Formula I.
  • sulphide 22 may also be converted to the sulphide 30 by reaction of 22 with a symmetrical sulfoxide in the presence of trimethylsilylchloride to give 30. Oxidation of 30 with a reagent such as m-chloroperoxybenzoic acid will give 29.
  • the silyl pyrrole 27 may also be acylated with an acid chloride to give the ketone 31. Removal of the silyl group from 31 and derivatization of the pyrrole will give compounds of Formula I.
  • Pyrroles such as 22 may also be sulphinylated directly without N-protection, by treatment with sulphinyl chlorides in a solvent such as dichloromethane at 0°C (J. Org. Chem. 5336, 1980). Oxidation as described above may provide pyrroles of Formula I where R 3 is SO 2 R 21 SCHEME VIII
  • the amino acid ester 32 may be acylated with an acid 33 that is suitably activated (acid chloride or other activating group used in amide coupling reactions) to give 34. Hydrolysis of the ester protecting group will privide 35. Cychzation by treament with an acid activating group such as DCC will give the oxazolium species 36. Addition of an alkyne 37 to 36 may give a pyrrole of Formula I via a 3+2 cycloaddition followed by loss of carbon dioxide. Various R 3 groups may be incorporated in this manner.
  • Aryl and heteroaryl rings are appended to the pyrrole ring system by utilization of organometallic coupling technology (Kalinin, V. Synthesis 413 1991). Two alternative approaches are utilized for appending aryl and heteroaryl rings to the pyrrole ring.
  • the pyrrole ring functions as the electrophile or as the nucleophile.
  • any of the two appended aromatic or heteroaromatic rings is attached to the pyrrole ring system (Alvarez, A. J. et al. J. Org. Chem. 1653, (1992) (use of boronic acid and tributyl stannanes for coupling to aromatic and heteroaromatic rings)).
  • Attachment of pyrrole pendant groups is carried out with or without other Ar, HAr, R 2 or R 3 groups attached.
  • R 2 groups are introduced through the use of the Heck reaction (Heck, R. F. Org. React. (1982), 27, 345) in which alkenes are coupled with heteroaryl halides.
  • Alkynes are coupled with heteroaryl halides to give alkyne substituents at R 2 .
  • R 2 alkene and alkyne groups may, in turn be reduced to alkanes by hydrogenation.
  • the synthesis of pyrroles containing nucleopilic groups for coupling reactions depends on the pyrrole substitution pattern. Lithium anions are prepared by metalation of a regioselectively halogenated pyrrole, or the regioselective deprotonation of the pyrrole preferably by the use of a directing functional group. The resulting anion may then be trapped by a trialkyl stannyl halide or a trialkyl borate or transmetalated to magnesium or zinc by treatment with appropriate halide salts.
  • a further method used to incorporate a trialkyl stannyl group is the coupling of a bromo, iodo or triflate substituted pyrrole with hexalkylditin in the presence of a palladium catalyst.
  • pyrroles incorporating electrophilic groups may be carried out by the regioselective halogentation of a pyrrole (Pyrroles Part 1 , R. Alan Jones.ed., Heterocyclic Compounds ,Vol 48 Part 1 , John Wiley, New York, 349-391 ,(1990)).
  • the regioselectivity of halogenation will depend on the size, nature and substitution position on the pyrrole ring as well as the presence or absence of the N-alkyl protecting group.
  • Triflates may be prepared by acylation of hydroxy pynoles with triflic anhydride.
  • reaction conditions used will depend on the nature of the coupling species.
  • the solvent used is normally toluene or DMF under anhydrous conditions.
  • boronic acid couplings a heterogenous system is used of water, toluene, dimethoxy ethane or ethanol in the presence of a base such as sodium carbonate or bicarbonate. In general the reaction takes place at an elavated temperature (80-100 °C).
  • Catalysts used depend on the structure of the components to be coupled as well as the functional groups. Most commonly, tetrakistriphenylphosphinepalladium (0) or palladium bis triphenyl phosphine dichloride are utilized.
  • Coupling chemistry may be utilized to introduce R 3 groups as shown below in Scheme X.
  • 4-unsubstituted pyrroles 22 may be halogenated by treatment with electrophilic sources of bromine and iodine to provide 38.
  • the halogen may then be coupled with carbon monoxide in the presence of an alcohol after the removal of any protecting groups to give 4-alkoxycarbonyl substituted pyrroles of formula I.
  • Treatment of 38 with a hexalkylditin in the presence of a palladium catalyst (see above for examples of catalysts) will give the stannyl pynole 39.
  • halogen metal exchange through treatment of 38 with an alkyl lithium followed by addition of a trialkyltinchloride will give 39.
  • the stannyl pyrrole may then be coupled to acid chlorides to give ketones of formula I. Reaction of 39 with chloro- sulfonylisocyanate in the presence of a palladium catalyst will give the sulphonyl isocyanate 40. 40 may subsequently be converted to a sulphonyl urea or sulphonyl carbamate of fomula I by addition of a primary or secondary amine or an alcohol.
  • Sulfides may be oxidized to sulfoxides and sulfones with reagents such as m-chloroperbenzoic acid. Sulfides may also be converted to sulfonyl chlorides by oxidation and chlorination by chlorine in water.
  • Sulphonyl chlorides may be converted to sulphonamides through the addition of ammonia or amines of Formula I.
  • Sulphonamides may be acylated with phosgene or carbonyl diimidazoles and then aminated with an amine to give sulphonyl ureas or treated with an alcohol to provide sulphonyl carbamates of Formula I.
  • Acylation of a sulphona- mide with an activated carboxylic acid will give an acyl suphonamide of Formula I.
  • Carboxylic acids may be activated by conversion to an acid chloride or reaction with a peptide coupling reagent such as carbonyl diimidazole or dicyclohexylcarbodiimide and then reacted with amines to give amides or sulphonamides to provide acylsulphonamides.
  • a peptide coupling reagent such as carbonyl diimidazole or dicyclohexylcarbodiimide
  • Primary amines are prepared from nitro groups by catalytic (Pd/C, H 2 or Raney Nickel, H 2 ) or chemical means (CoCl 2 , NaBH 4 ).
  • Alkylation of amines to give secondary and tertiary amines is achieved by reductive alkylation (aldehyde, NaCNBH 4 ) or alkylation with an alkyl group substituted with a leaving group in the presence of a base such as K 2 CO 3 .
  • Tertiary amines may, alternatively, be carried through the reaction sequences to the pyrroles.
  • chlorosufonates will give rise to amides, carbamates, ureas and
  • amides and ureas are useful: such as for example, treatment of the amine with phosgene, or an equivalent thereof, followed by acyaltion of an alcohol or amine with the intermediate activated chloroformamide.
  • Carboxylic acids are best introduced as esters early in the synthesis. Saponification will provide carboxylic acids. Transesterification or esterification of the acids will give esters.
  • Carboxylic acids may be converted to amides by activation and reaction with amines.
  • Phenols are best introduced in a protected form early in the synthetic sequence to the pyrrole. Removal of the protecting group provides a phenol which may subsequently be alkylated in the presence of an alkylating agent and base to give an ether, or acylated with an isocyanate to give carbamates.
  • Phenols may be converted to aryl ethers by reaction with an aryl bismuthane in the presence of copper II acetate.
  • Aryl and heteroaryl groups may be attached to pyrrole pendant aryl and heteroaryl groups by application of coupling chemistry technology as outlined above.
  • Aryl and heteroaryl rings are appended to the pyrrole ring system by utilization of organometallic coupling technology (Kalinin, V. Synthesis 413 1991).
  • the pyrrole ring functions as the electrophile or as the nucleophile.
  • Lithium anions are prepared by metalation of a regioselectively halogenated pyrrole, or the regioselective deprotonation of the pyrrole preferably by the use of a directing functional group.
  • the resulting anion may then be trapped by a trialkyl stannyl halide or a trialkyl borate or transmetalated to magnesium or zinc by treatment with appropriate halide salts.
  • a further method used to incorporate a trialkyl stannyl group is the coupling of a bromo, iodo or triflate substituted pyrrole with hexalkylditin in the presence of a palladium catalyst.
  • pyrroles incorporating electrophilic groups may be carried out by the regioselective halogentation of a pyrrole (Pyrroles Part 1 , R. Alan Jones.ed., Heterocyclic Compounds ,Vol 48 Part 1 , John Wiley, New York, 349-391 ,(1990)).
  • the regioselectivity of halogenation will depend on the size, nature and substitution position on the pyrrole ring as well as the presence or absence of the N-alkyl protecting group.
  • Triflates may be prepared by acylation of hydroxy pynoles with triflic anhydride.
  • reaction conditions used will depend on the nature of the coupling species.
  • the solvent used is normally toluene or DMF under anhydrous conditions.
  • boronic acid couplings a heterogenous system is used of water, toluene, dimethoxyethane or ethanol in the presence of a base such as sodium carbonate or bicarbonate. In general the reaction takes place at an elavated temperature (80-100 °C).
  • Catalysts used depend on the structure of the components to be coupled as well as the functional groups. Most commonly, tetrakistriphenylphosphinepalladium (0) or palladium bis triphenyl phosphine dichloride are utilized.
  • the preparation of 4-halo substituted pyrroles may be accomplished by treatment of 2,3,5, trisubstituted pyrroles with halogens.
  • Alkyl substituents at the 4 position of the pyrrole may be introduced through the synthesis of the 1 ,2,3,4-tetrasubstituted 1 ,4-diketone followed by cychzation with ammonia or an amine.
  • coupling of alkenes or alkynes with 4-halo pyrroles (Heck reaction, see Kalinin, V. Synthesis 413 (1991 ) for a review) will give rise to alkenyl and alkynyl substituted pyrroles that may be reduced or otherwise modified to provide compounds of formula I.
  • Sulfides may be oxidized to sulfoxides and sulfones with reagents such as m-chloroperbenzoic acid. Sulfides may also be converted to sulfonyl chlorides by oxidation and chlorination by chlorine in water.
  • Primary amines are prepared from nitro groups by catalytic (Pd/C, H 2 or Raney Nickel, H 2 ) or chemical means (CoCl 2 , NaBH 4 ).
  • Alkylation of amines to give secondary and tertiary amines is achieved by reductive alkylation (aldehyde, NaCNBH 4 ) or alkylation with an alkyl group substituted with a leaving group in the presence of a base such as K 2 CO 3 .
  • Tertiary amines may, alternatively, be carried through the reaction sequences to the pynoles.
  • chlorosufonates will give rise to amides, carbamates, ureas and
  • amides and ureas are useful: such as for example, treatment of the amine with phosgene, or an equivalent thereof, followed by acyaltion of an alcohol or amine with the intermediate activated chloroformamide.
  • Carboxylic acids are best introduced as esters early in the synthesis. Saponification will provide carboxylic acids. Transesterification or esterification of the acids will give esters. Carboxylic acids may be converted to amides by activation and reaction with amines.
  • Phenols are best introduced in a protected form early in the synthetic sequence to the pyrrole. Removal of the protecting group provides a phenol which may subsequently be alkylated in the presence of an alkylating agent and base to give an ether, or acylated with an isocyanate to give carbamates. Phenols may be converted to aryl ethers by reaction with an aryl bismuthane in the presence of copper II acetate.
  • Aryl and heteroaryl groups may be attached to pyrrole pendant aryl and heteroaryl groups by application of coupling chemistry technology as outlined above.
  • Suitable hydroxyl protecting groups are:
  • t-butylmethoxyphenylsilyl t-butoxydiphenylsilyl, trimethylsilyl, triethylsilyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, benzyloxycarbonyl, t-butyloxycarbonyl, 2,2,2-trichloroethyloxycarbonyl, and ally loxy carbonyl.
  • carboxyl protecting groups are benzhydryl, o-nitrobenzyl, p-nitrobenzyl, 2-naphthylmethyl, allyl, 2-chloroallyl, benzyl, 2,2,2-trichloroethyl, trimethylsilyl, t-butyldimethoylsilyl, t-butldiphenylsilyl, 2-(trimethylsilyl)ethyl, phenacyl, p-methoxybenzyl, acetonyl, p-methoxyphenyl, 4-pyridylmethyl and t-butyl.
  • a solution of pinacolone (0.01 m) in 10 ml of THF -78°C is treated with a solution of sodium hexamethyl disilazide (0.01 1 m) in THF. After stirring for 10 minutes a solution of 4-fluorobromoacetophenone (0.011 m) in THF is added. The reaction mixture is allowed to warm to room temperature over 2 hours. 20 ml of water is added and the reaction mixture is extracted with ethyl acetate (3 ⁇ 10 ml). The combined organic phases are washed with brine and dried over MgSO 4 . The mixture is filtered and the filtrate is concentrated in vacuo. The product is purified by flash chromatography over silica gel.
  • Step 1 The product of Step 1 is dissolved in acetic acid and treated with 10 times its weight of ammonium acetate. The mixture is heated at 1 10°C for 2 hours, cooled to room temperature and diluted with water and ethyl acetate. The aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with brine and dried over MgSO 4 . The mixture is filtered and the filtrate is concentrated in vacuo to provide the product. The product is purified further by recrystalization or chromatography over silica gel.
  • step 2 The product of step 2 is dissolved in THF and treated with
  • a solution of the product of Step 3 in THF at -75°C is treated with 1.1 eqivalents of N-bromosuccinimide portionwise over 1 hour.
  • the reaction mixture is allowed to warm to 0°C over 2 hours and then stined over night.
  • the reaction mixture is concentrated in vacuo and then triturated with carbon tetrachloride.
  • the solid succinimide is removed by filtration and the filtrate is concentrated in vacuo to give the desired product.
  • a solution of the product of Step 4 in DMF is treated with 1.5 equivalents of 3-trimethylstannyl pyridine and 0.1 equivalents of bis-triphenylphosphine palladium dichloride.
  • the reaction mixture is heated to 90°C for 3 hours, cooled and diluted with ethyl acetate and is washed with water.
  • the organic phase are washed with brine and dried over MgSO 4 .
  • the mixture is filtered and the filtrate is concentrated in vacuo to provide the product.
  • the product is purified by flash chromatography over silica gel.
  • a solution of the product of Step 5 in DMF is treated with 3-chloropyridine and 0.1 equivalent of bis(triphenylphosphine) palladium dichloride.
  • the reaction mixture is heated at 100°C until the starting material is consumed.
  • the mixture is diluted with ethyl acetate and washed with water and brine, and is then dried over MgSO 4 .
  • the mixture is filtered and the residue is concentrated in vacuo.
  • the residue is purified by flash chromatography over silica gel.
  • Step 2 The product of Step 2 was dissolved in 1.0 mL of acetic acid
  • Step 2 The product of Step 2 is treated with ammonium acetate as described above in Preparative Example 1.
  • a mixture of ethyl 3-keto-heptanoate, 0.7 equivalents of the product of Step 1 and 4 equivalents of ammonium acetate are heated in acetic acid at reflux until the benzoin is consumed.
  • the reaction mixture is diluted with ethyl acetate and washed with water and brine and dried over MgSO 4 .
  • the mixture is filtered and the filtrate is concentrated in vacuo and the residue is purified by chromatography over silica gel to give the desired product.
  • a mixture of 1-(4-N-methylpiperidinyl)-2-cyanoethanone, 0.7 equivalents of the reaction product of Example 1 , Step 1 , and 4 equivalents of ammonium acetate are heated in acetic acid at reflux until the benzoin is consumed.
  • the reaction mixture is diluted with EtOAc and washed with water and brine and dried over MgSO 4 .
  • the mixture is filtered and the filtrate is concentrated in vacuo and the residue is purified by chromatography over silica gel to give the desired product.
  • Example 3 The product of Example 3 is reacted with 1.05 equivalents of meta-chloroperoxybenzoic acid in CH 2 Cl 2 at 0°C. The reaction mixture is stirred overnight at room temperature. The solution is diluted with EtOAc and washed with saturated sodium bicarbonate solution followed by brine. The solution is dried over MgSO4, filtered and concentrated in vacuo. The residue is purified by silica gel chromatography to produce the desired product.
  • Example 6 The product of Example 6 is heated with excess lithium hydroxide in DME/water at reflux until the conversion to the acid is complete.
  • the reaction mixture is acidified with acetic acid and extracted with ethyl acetate to give the desired product.
  • Example 4 The product of Example 4 is dissovled in t-butyl alcohol and methyl 2- butene (6: 1 ratio). The solution is then treated with 1.5 eq of monobasic sodium phosphate and an aqueous solution of sodium chlorate. The reaction mixture is stirred at room temperature until the sm is consumed. The pH is adjusted to 5.5 with dilute HCl. The product is extracted with ethyl acetate and the combined organic phase is washed with water and brine and dried over MgSO 4 . The mixture is filtered and the filtrate is concentrated in vacuo to give the desired product.
  • Example 8 The product of Example 8 is dissolved in DMF and treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, benzyl amine and Hunigs base and a catalytic amount of DMAP. The mixture is stirred overnight at room temperature. The solution is diluted with water and extracted with ethyl acetate. The organic phase is washed with water and brine and is dried over MgSO 4 , filtered and concentrated in vacuo. The residue is purified by chromatography. EXAMPLES 1 1-66
  • PBMC Human peripheral blood mononuclear cells
  • PBMC's are washed three times in Hanks Balanced Salt Solution and then resuspended to a final concentration of 2 ⁇ 10 6 cell/mL in RPMI containing 10% fresh autologous human serum, penicillin streptomycin (10 U/mL) and 0.05% DMSO.
  • Lipopolysaccharide (Salmonella type Re545; Sigma Chemicals) is added to the cells to a final concentration of 100 ng/mL.
  • An aliquot (0.1 mL) of the cells is quickly dispensed into each well of a 96 well plate containing 0.1 mL of the test compound, at the appropriate dilution, and are incubated for 24 hours at 37°C in 5% CO 2 .
  • cell culture supernatants are assayed for IL-1 ⁇ , TNF- ⁇ , IL-6 and PGE 2 production using specific ELISA.
  • Human peripheral blood mononuclear cells are isolated from fresh human blood according to the procedure of Chin and Kostura, J. Immunol. 151, 5574-5585 (1993). Whole blood is collected by sterile venipuncture into 60 mL syringes coated with 1.0 mL of sodium- heparin (Upjohn, 1000 U/mL) and diluted 1 :1 in Hanks Balanced Salt Sooution (Gibco). The erythrocytes are separated from the PBMC's by
  • PBMC's are washed three times in Hanks Balanced Salt Solution and then resuspended to a final concentration of 2 ⁇ 10 6 cell/mL in RPMI containing 10% fresh autologous human serum, penicillin streptomycin (10 U/mL) and 0.05% DMSO. Endotoxin free recombinant human IL-1 ⁇ is then added to a final concentration of 50 pMolar.
  • Human IL-1 ⁇ can be detected in cell-culture supernatants or whole blood with the following specific trapping ELISA.
  • Ninety-six well plastic plates (Immulon 4; Dynatech) are coated for 12 hours at 4°C with 1 mg/mL protein-A affinity chromatography purified mouse anti-human IL-lb monoclonal antibody (purchased as an ascites preparation from LAO Enterprise, Gaithersburg Maryland.) diluted in Dulbecco's phosphate-buffered saline (-MgCl 2 , -CaCl 2 ). The plates are washed with
  • IL-1 ⁇ standards are prepared from purified recombinant IL-1 ⁇ produced from E. coli. The highest concentration begins at 10 ng/mL followed by 11 two-fold serial dilutions. For detection of IL-l ⁇ from cell culture supernatants or blood plasma, 10 - 25 mL of supernatant is added to each test well with 75 -90 mL of PBS Tween.
  • Peroxidase activity was determined using TMB peroxidase substrate kit (Kirkegaard and Perry) with quantitation of color intensity on a 96-well plate Molecular Devices spectrophotometer set to determine absorbance at 450 nM. Samples are evaluated using a standard curve of absorbance versus concentration. Four-parameter logistics analysis generally is used to fit data and obtain concentrations of unknown compounds.
  • Immulon 4 (Dynatech) 96-well plastic plates are coated with a 0.5 mg/mL solution of mouse anti-human TNF- ⁇ monoclonal antibody.
  • the secondary antibody is a 1 :2500 dilution of a rabbit anti-human TNF- ⁇ polyclonal serum purchased from Genzyme. All other operations are identical to those described above for IL-1b.
  • the standards are prepared in PBS-Tween + 10% FBS or HS. Eleven 2 fold dilutions are made beginning at 20 ng/mL TNF- ⁇ .
  • IL-6 levels are also determined by specific trapping ELISA as described previously in Chin and Kostura, J. Immunol. 151, 5574-5585 (1993). (Dynatech) ELISA plates are coated with mouse anti-human IL-6 monoclonal antibody diluted to 0.5 mg/ml in PBS. The secondary antibody, a rabbit anti-human IL-6 polyclonal antiserum, is diluted 1 :5000 with PBS-Tween. All other operations are identical to those described above for IL-1 ⁇ . The standards are prepared in PBS-Tween + 10% FBS or HS. Eleven 2 fold dilutions are made beginning at 50 ng/mL IL-6.
  • Prostaglandin E2 is detected in cell culture supernatants from LPS or IL-1 stimulated PBMC's using a commercially available enzyme immunoassay .
  • the assay purchased from the Cayman Chemical (Catalogue number 514010) and is run according to the manufacturers instructions.
  • Interleukin8 (IL-8)
  • the present compounds can also be assayed for IL-8 inhibitory activity as discussed below.
  • Primary human umbilical cord endothelial cells (HUVEC) (Cell Systems, Kirland, Wa) are maintained in culture medium supplemented with 15% fetal bovine serum and 1 % CS-HBGF consisting of aFGF and heparin. The cells are then diluted 20- fold before being plated (250 ⁇ l) into gelatin coated 96-well plates. Prior to use, culture medium is replaced with fresh medium (200 ⁇ l). Buffer or test compound (25 ⁇ l, at appropriate concentrations) is then added to each well in quadruplicate wells and the plates incubated for 6h in a humidified incubator at 37°C in an atmosphere of 5% CO 2 .
  • IL-8 ELISA kit obtained from R&D Systems (Minneapolis, MN). All data is presented as mean value (ng/ml) of multiple samples based on the standard curve. IC 50 values where appropriate can be generated by non-linear regression analysis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Arylpyrroles substitués, ainsi que compositions contenant ces composés et procédés de traitement. Les maladies liées aux cytokines sont des maladies ou états pathologiques dans lesquels une ou plusieurs cytokines présentent une production ou une activité excessives ou non régulées. L'interleukine-1 (IL-1), l'interleukine-6 (IL-6), l'interleukine-8 (IL-8) et le facteur de nécrose des tumeurs (TNF) sont des cytokines impliquées dans ces états pathologiques.
PCT/US1996/017477 1995-10-31 1996-10-28 Arylpyrroles substitues, compositions contenant ces composes et procedes d'utilisation desdits composes WO1997016426A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75290/96A AU7529096A (en) 1995-10-31 1996-10-28 Substituted aryl pyrroles, compositions containing such compounds and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US711595P 1995-10-31 1995-10-31
US60/007,115 1995-10-31
GBGB9602835.2A GB9602835D0 (en) 1996-02-13 1996-02-13 Substituted aryl pyrroles compositions containing such compounds and methods of use
GB9602835.2 1996-02-13

Publications (1)

Publication Number Publication Date
WO1997016426A1 true WO1997016426A1 (fr) 1997-05-09

Family

ID=26308659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017477 WO1997016426A1 (fr) 1995-10-31 1996-10-28 Arylpyrroles substitues, compositions contenant ces composes et procedes d'utilisation desdits composes

Country Status (2)

Country Link
AU (1) AU7529096A (fr)
WO (1) WO1997016426A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002430A1 (fr) * 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Composes de pyridylpyrrole utiles comme antagonistes de l'interleukine et du facteur tnf
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
WO2001034149A1 (fr) * 1999-11-12 2001-05-17 Merck & Co., Inc. Derives de diaryle piperidyle pyrrole en tant qu'agents antiprotozoaires
US6268370B1 (en) 1992-01-13 2001-07-31 Smithkline Beecham Corporation Compounds
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6602877B1 (en) 1997-06-12 2003-08-05 Aventis Pharma Limited Imidazolyl-cyclic acetals
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
US6730683B2 (en) 1997-12-19 2004-05-04 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6774127B2 (en) 1997-06-13 2004-08-10 Smithkline Beecham Corporation Pyrazole and pyrazoline substituted compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
JP2006520386A (ja) * 2003-03-13 2006-09-07 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5442060A (en) * 1992-09-29 1995-08-15 Mitsubishi Kasei Corporation Carboxamide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5442060A (en) * 1992-09-29 1995-08-15 Mitsubishi Kasei Corporation Carboxamide derivatives

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268370B1 (en) 1992-01-13 2001-07-31 Smithkline Beecham Corporation Compounds
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US6417202B1 (en) 1996-07-11 2002-07-09 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin-and TNF antagonists
WO1998002430A1 (fr) * 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Composes de pyridylpyrrole utiles comme antagonistes de l'interleukine et du facteur tnf
US6989395B2 (en) 1997-06-12 2006-01-24 Aventis Pharma Limited Imidazolyl-cyclic acetals
US6602877B1 (en) 1997-06-12 2003-08-05 Aventis Pharma Limited Imidazolyl-cyclic acetals
US6774127B2 (en) 1997-06-13 2004-08-10 Smithkline Beecham Corporation Pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6184237B1 (en) 1997-11-07 2001-02-06 Amgen Inc. Substituted pyridine compounds and methods of use
US6333341B1 (en) 1997-11-07 2001-12-25 Amgen Inc. Substituted pyridine compounds and methods of use
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6458813B1 (en) 1997-11-07 2002-10-01 Amgen Inc. Substituted pyridine compounds and methods of use
US6730683B2 (en) 1997-12-19 2004-05-04 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6861417B2 (en) 1998-11-04 2005-03-01 Smithkline Beecham Corporation Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2001034149A1 (fr) * 1999-11-12 2001-05-17 Merck & Co., Inc. Derives de diaryle piperidyle pyrrole en tant qu'agents antiprotozoaires
US6384052B1 (en) 1999-11-12 2002-05-07 Merck & Co., Inc. Anticoccidial compounds
AU781552B2 (en) * 1999-11-12 2005-05-26 Merck Sharp & Dohme Corp. Diaryl piperidyl pyrrole derivatives as antiprotozoal agents
JP2003527336A (ja) * 1999-11-12 2003-09-16 メルク エンド カムパニー インコーポレーテッド 抗原虫薬としてのジアリールピペリジルピロール誘導体
US6291480B1 (en) 1999-11-12 2001-09-18 Merck & Co., Inc. Diaryl piperidyl pyrrole derivatives as antiprotozoal agents
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7612094B2 (en) 2002-04-04 2009-11-03 Biogen Idec Ma Inc. Tri-substituted heteroaryls and methods of making and using the same
JP2006520386A (ja) * 2003-03-13 2006-09-07 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
JP4808154B2 (ja) * 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物

Also Published As

Publication number Publication date
AU7529096A (en) 1997-05-22

Similar Documents

Publication Publication Date Title
EP0863757B1 (fr) Pyrroles d'aryle substitues en position 2, compositions contenant de tels composes et leurs modes d'utilisation
US5837719A (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
AU6769196A (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
AU747755B2 (en) Substituted imidazoles having cytokine inhibitory activity
WO1997016426A1 (fr) Arylpyrroles substitues, compositions contenant ces composes et procedes d'utilisation desdits composes
US6288062B1 (en) Oxazoles for treating cytokine mediated diseases
WO1997016442A1 (fr) Pyrroles de pyridyle substitues, compositions contenant de tels composes et mode d'utilisation
US5792778A (en) 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
JP3264492B2 (ja) ピリジル置換イミダゾール
EP0906307B1 (fr) Imidazoles substitues inhibant la cytokine
AU784484B2 (en) Substituted 2-aryl-3(heteroaryl)-imidazo(1,2-a) pyrimidines, and related pharmaceutical compositions and methods
WO1997016441A1 (fr) Pyrroles aryliques de substitution, compositions renfermant de telles composes et methodes d'utilisation de ces substances
US6492516B1 (en) Compounds having cytokine inhibitory activity
KR19990022574A (ko) 이미다졸 화합물
JP2002530399A (ja) サイトカイン阻害活性を有する化合物
US6403596B1 (en) Substituted pyridones having cytokine inhibitory activity
JP2003503458A (ja) サイトカイン阻害活性を有する化合物
US20020169173A1 (en) Oxazoles for treating cytokine mediated diseases
WO2001022965A1 (fr) Imizadoles substitues a activite inhibitrice de la cytokine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97517547

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA